康宁杰瑞(09966.HK)向石药(01093.HK)授出JSKN003内地独家许可权

阿斯达克财经
29 Sep 2024

康宁杰瑞制药-B(09966.HK) 公布,与石药集团(01093.HK) 订立许可协议。据此,石药集团获得在内地开发、销售、许诺销售及商业化JSKN003(用于治疗肿瘤相关适应症)的独家许可及再许可权,并成为该地区JSKN003用于该领域的唯一上市许可持有人。公司有权收取最高合共人30.8亿人民币的预付款及里程碑付款。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-09-27 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10